Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: Therapeutic implications for tubulointerstitial fibrosis

Nephron - Experimental Nephrology

Volumn 97, Issue 4, 2004, Pages

  Ikeuchi, Hidekazu ^a   Kuroiwa, Takashi ^a   Yamashita, Shin ^a   Hiramatsu, Noriyuki ^a   Maeshima, Akito ^a   Kaneko, Yoriaki ^a   Hiromura, Keiju ^a   Ueki, Kazue ^a   Nojima, Yoshihisa ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Collagen; Cyclin A; Fluvastatin; G1 arrest; Hydroxymethylglutaryl CoA reductase inhibitors; NRK 49F; p27kip1; Tubulointerstitial fibrosis

Indexed keywords

COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; MESSENGER RNA; MEVALONIC ACID; PROTEIN P27; RHO FACTOR;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; EXAMINATION; EXTRACELLULAR MATRIX; FIBROBLAST; INTERSTITIAL NEPHRITIS; KIDNEY CELL; MODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; UPREGULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; DOSE RESPONSE; GROWTH INHIBITION; KIDNEY; KIDNEY FIBROSIS; KIDNEY TUBULE;

ACUTE-PHASE PROTEINS; ANIMALS; CELL CYCLE PROTEINS; CELL LINE; CELL PROLIFERATION; COLLAGEN TYPE III; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FATTY ACIDS, MONOUNSATURATED; FIBROBLASTS; FIBROSIS; G1 PHASE; IMMEDIATE-EARLY PROTEINS; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY TUBULES; MEVALONIC ACID; NEPHRITIS, INTERSTITIAL; POLYISOPRENYL PHOSPHATES; RATS; TUMOR SUPPRESSOR PROTEINS;

EID: 4444293706     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079176     Document Type: Article

References (30)

1. Massy ZA, Keane WF, Kasiske BL: Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction? Lancet 1996;347:102-103.
2. Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D-11D.
3. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
4. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T: Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 1998;9:2027-2039.
5. 1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:80-87.
6. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina N: Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000;67:427-431.
7. Lee TM, Su SF, Tsai CH: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002;40:67-73.
8. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-570.
9. Nishimura M, Tanaka T, Yasuda T, Kurakata S, Kitagawa M, Yamada K, Saito Y, Hirai A: Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Kidney Int Suppl 1999;71:97-100.
10. Massy ZA, Guijarro C, Oda H, Kasiske BL, Keane WF, O'Donnell MP: Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. Kidney Int Suppl 1999;71:80-83.
11. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301-8305.
12. Grandaliano G, Biswas P, Choudhury GG, Abboud HE: Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993;44:503-508.
13. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 1997;52:1016-1027.
14. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF: Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 1995;48:363-371.
15. Miyazaki K, Isbel NM, Lan HY, Hattori M, Ito K, Bacher M, Bucala R, Atkins RC, Nikolic-Paterson DJ: Up-regulation of macrophage colony-stimulating factor and migration inhibitory factor expression and monocyte recruitment during lipid-induced glomerular injury in the exogenous hypercholesterolaemic rat. Clin Exp Immunol 1997;108:318-323.
16. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998;31:190-194.
17. Risdon RA, Sloper JC, De Wardener HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;ii:363-366.
18. Zeisberg M, Strutz F, Muller GA: Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000;13(suppl 3):111-120.
19. Moriyama T, Kawada N, Nagatoya K, Takeji M, Horio M, Ando A, Imai E, Hori M: Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001;59:2095-2103.
20. Takagi C, Ueki K, Ikeuchi H, Kuroiwa T, Kaneko Y, Tsukada Y, Maezawa A, Mitaka T, Sasaki T, Nojima Y: Increased expression of cell adhesion kinase β in human and rat crescentic glomerulonephritis. Am J Kidney Dis 2002;39:174-182.
21. Tanaka T, Kuroiwa T, Ikeuchi H, Ota F, Kaneko Y, Ueki K, Tsukada Y, McInnes IB, Boumpas DT, Nojima Y: Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol 2002;13:2488-2496.
22. Laufs U, Liao JK: Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-148.
23. Ghosh PM, Mott GE, Ghosh-Choudhury N, Radnik RA, Stapleton ML, Ghidoni JJ, Kreisberg JI: Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim Biophys Acta 1997;1359:13-24.
24. Buemi M, Allegra A, Senatore M, Marino D, Medici MA, Aloisi C, Di Pasquale G, Corica F: Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999;370:201-203.
25. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
26. 1 and myofibroblasts: A potential pathway towards renal scarring in human glomerular disease. Nephron 2001;87:240-248.
27. Kelynack KJ, Hewitson TD, Martic M, McTaggart S, Becker GJ: Lovastatin downregulates renal myofibroblast function in vitro. Nephron 2002;91:701-709.
28. Kip1. J Biol Chem 1999;274:21926-21931.
29. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, Nakao K: Role of connective tissue growth factor in profibrotic action of transforming growth factor-β: A potential target for preventing renal fibrosis. Am J Kidney Dis 2001;38:S134-S138.
30. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M: Rho-dependent inhibition of the induction of connective tissue growth factor by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-1180.